United Health Products Updates on CelluSTAT Clinical Study
United Health Products, Inc. (OTCPK: UEEC) has recently provided an important update regarding its clinical study process. As the company progresses, transparency and effective communication remain vital in keeping stakeholders informed about significant advancements.
Overview of the Clinical Trial Process
United Health Products is actively conducting a clinical trial for its innovative CelluSTAT Hemostatic Gauze product, which was previously known as HemoStyp. This initiative, prompted by a request from the FDA, aims to gather additional clinical data to reinforce the product's efficacy and safety profiles. An integral step was the submission of an Investigational Device Exemption (IDE) application to the FDA, which serves as a prerequisite for patient enrollment in the upcoming study.
FDA IDE Submission and Response Timeline
The IDE submitted includes a comprehensive study protocol that plans to test around 30 subjects across several surgical sites, targeting objectives that will confirm both non-inferiority and superiority of CelluSTAT in comparison to standard care during open surgical procedures within the abdominal cavity. The FDA is expected to review IDE applications typically within a 30-day window, depending on resource availability.
Collaboration with Research Organizations
Alongside IDE preparations, United Health Products has taken proactive measures by soliciting proposals from various contract research organizations (CROs) to collaborate on managing the clinical study. These partnerships are crucial for ensuring rigorous adherence to Good Clinical Practice, which is paramount for the integrity of clinical trials.
Choosing a CRO for Clinical Study Management
After careful consideration, the company has selected a suitable CRO partner that will assist in project management, site monitoring, and safety oversight throughout the study. Additionally, United Health Products has initiated discussions with surgical center operators to identify appropriate sites for carrying out the clinical trials. This groundwork will allow the company to finalize site evaluations rapidly, set up training for site investigators, and engage a Central Institutional Review Board (IRB) to ensure proper oversight of the study.
Addressing Financial Needs and Future Plans
For the successful execution and analysis of the clinical study, securing external funding is essential. The company is currently in negotiation talks with various capital providers, including long-time investors, to meet its financial requirements while minimizing potential dilution for existing shareholders. United Health Products aims to define investment terms through a private placement strategy that supports its long-term vision.
Market Strategies and Board Expansion
In light of the historically low market price of its common shares, United Health Products recognizes the challenges that some investors are facing in achieving liquidity with their holdings. To enhance market conditions, the company is exploring several strategies, including expanding its Board of Directors, forming a qualified Audit Committee, and hiring an external investor relations firm. Furthermore, the company is considering an uplisting from the OTC Markets to a more established trading platform, which it anticipates could be completed in the early part of the coming year, assuming capital needs are met.
Continuous Communication and Transparency
United Health Products commits to maintaining open lines of communication with stakeholders through regular press releases. These updates will cover the progression of the clinical study along with developments regarding the corporate actions listed above. While the future looks promising, the company acknowledges that approval for its Premarket Approval (PMA) application is not guaranteed.
About United Health Products
United Health Products has made strides in developing a unique Neutralized Regenerated Cellulose hemostatic agent known as CelluSTAT. Designed as a natural solution for controlling mild to moderate bleeding, UHP is on a promising path to seek approval to enter the human surgical market effectively.
Contact Information
For more information about United Health Products and its ongoing projects, you can visit their new website or reach out via email. Additionally, they are accessible through phone or text at 475.755.1005.
Frequently Asked Questions
What is the current status of the clinical study for CelluSTAT?
The clinical study for CelluSTAT is ongoing, with the company having submitted an IDE application to the FDA for review.
How many subjects will be involved in the clinical trial?
The clinical trial aims to test approximately 30 subjects across multiple surgical facilities.
What are the main objectives of the clinical study?
The study seeks to confirm the non-inferiority and superiority of CelluSTAT compared to the standard of care during open surgical procedures.
What funding strategies is United Health Products pursuing?
United Health Products is negotiating with potential capital providers to secure external funding while minimizing dilution for shareholders.
What actions is UHP taking to improve its market presence?
The company is expanding its Board, establishing an Audit Committee, and considering a move to a more reputable trading platform to attract a wider range of investors.
